{'fraction_non_alphanumeric': 0.03322259136212625, 'fraction_numerical': 0.02040816326530612, 'mean_word_length': 5.110144927536232, 'pattern_counts': {'":': 0, '<': 5, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions.

PURPOSE
To explore the efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on the expressions of esophageal cancer-related gene 4 (ECRG4) and vascular endothelial growth factor (VEGF).


METHODS
86 patients with nasopharyngeal carcinoma, admitted to and treated in our hospital from March 2016 to February 2018, were selected and randomly divided into control group (n=43) and observation group (n=43). Chemotherapy combining cisplatin with fluorouracil was administered in the control group, while nedaplatin combined with docetaxel was given in the observation group. Then the efficacy, adverse reactions, the levels of serum hypoxia-inducible factor-1α (HIF-1α) and VEGF in patients before and after treatment, and the change in the expression level of ECRG4 in foci after treatment were compared between the two groups. After 1-year follow-up, the improvement in quality of life was compared between the two groups of patients.


RESULTS
The objective remission rate and disease control rate in the observation group were obviously higher than in the control group (p<0.05), and the total incidence rate of adverse reactions in the observation group was evidently lower than in the control group (p<0.05). At 2, 4, and 6 weeks after treatment, the two groups of patients had substantially decreased levels of serum HIF-1α and VEGF, and the declines were more apparent in the observation group (p<0.05). The expression level of ECRG4 in foci in the observation group was remarkably higher than in the control group (p<0.05). The observation group exhibited more apparent improvement in quality of life than the control group (p<0.05).


CONCLUSIONS
Nedaplatin combined with docetaxel has better short-term efficacy in nasopharyngeal carcinoma, with milder adverse reactions, and it can reduce the levels of serum HIF-1α and VEGF, and up-regulate ECRG4 expression in patients, exerting an anti-carcinoma effect.